- Physics - 14:00 "move" through to the next round
- Physics - 13:30 Empa mobility demonstrator "move"
- Medicine - 09:30 First international higher education program in sleep medicine
- Environment - Jun 20 Federal Council adopts Switzerland's country report on implementation of the 2030 Agenda
- Medicine - Jun 19 Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
- Astronomy - Jun 18 An EPFL- designed rocket competes in the United States
- Medicine - Jun 18 Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to- head trial post- cataract surgery
- Medicine - Jun 16 Novartis JULIET trial of Kymriah demonstrates more than one- year durability of responses in adults with relapsed or refractory DLBCL
wire - news in brief
Environment Jun 21
Medicine Jun 20
Researchers from ETH Zurich and EPFL have discovered a new type of fat cell that suppresses the growth of new fat cells.
Medicine Jun 20
A study led by researchers in Switzerland has revealed a new cell type that resides in the body's fat depots where it can actively suppress fat cell formation.
Category
Results 1 - 50 of 269.
Around two years ago, Empa opened "move", the demonstrator for the mobility of the future, with a view to revealing various paths for mobility with renewable energy.
Around two years ago, Empa opened "move", the demonstrator for the mobility of the future, with a view to revealing various paths for mobility with renewable energy.
Federal Council adopts Switzerland's country report on implementation of the 2030 Agenda
Bern, 20.06.2018 - At its meeting on 20 June 2018, the Federal Council adopted Switzerland's country report on the implementation of the 2030 Agenda for Sustainable Development.
Bern, 20.06.2018 - At its meeting on 20 June 2018, the Federal Council adopted Switzerland's country report on the implementation of the 2030 Agenda for Sustainable Development.
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery Better visual outcomes for patients with t
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery Better visual outcomes for patients with t
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable Patients had a 65% chance of being relapse-free o
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable Patients had a 65% chance of being relapse-free o
Study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer Comparison of Jakavi (ruxolitinib) vs.
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer Comparison of Jakavi (ruxolitinib) vs.
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients’ quality of life
Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients
Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients
The young startup of the University of Basel, Qnami, is the winner of the Venture Kick prize worth 130'000 Swiss Francs.
Fats are essential for our body. The core components of all fats are fatty acids. Their production is initiated by the enzyme ACC.
This year the newly opened Innovation Park Zurich repurposed old hangars on the military airfield in Dübendorf into office space, creating a novel combination of airfield and laboratory. This site is now where the UZH Space Hub carries out joint research projects of the University of Zurich and its partners from air and space travel.
Doris Leuthard, head of Switzerland's Federal Department of the Environment, Transport, Energy and Communications, takes a hands-on approach.
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs Patients repor
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs Patients repor
Peatland Protection Equals Efficient Climate Protection
Zurich-Reckenholz, 07.06.2018 - Is there a cost-efficient way to curb climate stress caused by land use? Globally, peatlands store twenty per cent of all the carbon lying untapped in the soil - despite the fact that they account for less than three per cent of the Earth's land mass. New findings from Agroscope show that peatland protection is a highly efficient climate-protection measure.
Zurich-Reckenholz, 07.06.2018 - Is there a cost-efficient way to curb climate stress caused by land use? Globally, peatlands store twenty per cent of all the carbon lying untapped in the soil - despite the fact that they account for less than three per cent of the Earth's land mass. New findings from Agroscope show that peatland protection is a highly efficient climate-protection measure.
EPFL start-up Picterra has devised a smart system that allows users to analyze drone or satellite images of a given territory: in a few clicks, they can extract information, statistics and representations of changes that have taken place in the area.
Hybrid overhead lines: More power, not more power lines
Social opposition to new high-voltage lines is delaying modernisation of the power grid. Two projects of the National Research Programmes "Energy Turnaround" and "Managing Energy Consumption" have determined the optimum design of hybrid overhead lines needed to increase the capacity of the power transmission grid and, at the same time, win popular acceptance for the new technology.
Social opposition to new high-voltage lines is delaying modernisation of the power grid. Two projects of the National Research Programmes "Energy Turnaround" and "Managing Energy Consumption" have determined the optimum design of hybrid overhead lines needed to increase the capacity of the power transmission grid and, at the same time, win popular acceptance for the new technology.
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy ENESTop and ENESTfreedom data evaluate Treatmen
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy ENESTop and ENESTfreedom data evaluate Treatmen
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion base
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion base
The way in which the phase-out of nuclear power plants in Germany is currently planned could negatively influence the safety of the facilities.
The research station at Jungfraujoch is at the top of Europe - and not only because of its unique location. Within the framework of the European research infrastructure «Integrated Carbon Observation System» (ICOS), the laboratory in the heart of the Alps is now officially certified. ICOS provides data to better understand the global carbon cycle and how human activities affect it.
From science to start-ups
The new Bridge programme helps to turn scientific research into actual products and services. A year and a half into its launch, the results are already in. "Without the financial support provided by Bridge, my discovery might have been relegated to the cemetery of good ideas that never materialized," says Olga Dubey, a biologist and a newly minted entrepreneur.
The new Bridge programme helps to turn scientific research into actual products and services. A year and a half into its launch, the results are already in. "Without the financial support provided by Bridge, my discovery might have been relegated to the cemetery of good ideas that never materialized," says Olga Dubey, a biologist and a newly minted entrepreneur.
FDA expedites review of Novartis drug Promacta for first-line severe aplastic anemia (SAA)
Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (
Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (
Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Phase III IMpower130 study showed Roche's Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to
Phase III IMpower130 study showed Roche's Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to
Out in the Cold or One of the Gang: Initial Contacts Set the Scene
Ostracism or social exclusion within a group serves to discipline disagreeable, awkward, or freeloading members and thus promote cooperation - at least this was the assumption of previous research in this field.
Ostracism or social exclusion within a group serves to discipline disagreeable, awkward, or freeloading members and thus promote cooperation - at least this was the assumption of previous research in this field.
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) These improvements were reported early by Entresto patients, with a median follow-up time of 32 days 21&
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) These improvements were reported early by Entresto patients, with a median follow-up time of 32 days 21&
EPFL projects make it past the first round to becoming FET Flagships
Two projects coordinated by EPFL - the Time Machine and Health EU - have made it into the second round of the selection process to become FET Flagships.
Two projects coordinated by EPFL - the Time Machine and Health EU - have made it into the second round of the selection process to become FET Flagships.
Complex reaction cascades can be triggered in artificial molecular systems: Swiss scientists have constructed an enzyme than can penetrate a mammalian cell and accelerate the release of a hormone.
A day as a young scientist
Physics isn't everyone's favourite subject. At the iLab of the Paul Scherrer Institute PSI, students experience the material in a different way: with experiments instead of memorising formulas.
Physics isn't everyone's favourite subject. At the iLab of the Paul Scherrer Institute PSI, students experience the material in a different way: with experiments instead of memorising formulas.
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related p
Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related p
Novartis data at ASCO and EHA reinforce company’s commitment to reimagining cancer
Results from the Kisqali MONALEESA clinical trial program, the largest industrysponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be pre
Results from the Kisqali MONALEESA clinical trial program, the largest industrysponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be pre
» Comment on this page.
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
